Businesswoman, 40, dies after excruciatingly painful plastic surgery procedure at famed doctor's luxury clinic
Natália Cavanellas, a well-known businesswoman, had the operation at San Gennaro Hospital in Mooca, São Paulo but went into cardiac arrest before she was declared dead, the São Paulo Department of Public Safety said.
Cavanellas' sister told police that she 'received first aid, but did not survive.'
The surgery was carried out by Dr. Edgar Lopez - who according to his website profile - claims to be an expert in high-definition liposuction, which is also known as liposculpture, and mammoplasty.
Lopez also claimed to have been the first doctor in the South American nation to have used Renuvion, a minimal invasive technology that tightens the skin whether a person undergoes liposuction or not.
Brazilian news outlet Metropoles reported that Lopez' private clinic, which is located in the São Paulo southern upscale neighborhood of Moema, was still open as of Tuesday.
Cavanellas leaves behind her husband, whom she married in 2019, and the couple's three-year-old daughter.
She ran her own public relations, marketing and events planning company, offering her support to a 'community with more than 800 businesswomen and executives'.
In March, Cavanellas was honored by the São Paulo City Council as one of the 100 most successful women in business.
Prior to going under the knife, Cavanellas shared a video clip of her birthday bash last week – the party also served as networking event for women.
'In a world full of superficial connections, I chose the opposite path: genuine, real relationships and connections,' she wrote.
'This is how NATworking came about, where networking meets entertainment, creating a lively and ideal environment for generating opportunities, business, partnerships and lasting friendships.
'Welcome to the fourth decade of my life! My purpose of connecting people and stories is growing stronger and stronger!'
Cavanellas' death stunned a tight-knit community of businesswomen who looked up to her.
'Thank you for all the love you always showed us,' podcaster Scheila Santo wrote. 'Congratulations on a beautiful journey, inspiring so many women! I am sure your daughter is very proud of the mom you are.'
'Nat has always been, and always will be, a go-to for me,' Carla Pinheiros said.
'She was unique in networking, positioning, transforming events into remarkable experiences,' the communications adviser added. 'May her legacy live on in all that she built and inspired.'
'Nat I'm still in disbelief,' wrote Dr. Larissa Saib. 'Just a short while ago we were together celebrating your life. I can't understand why God took you now.'
The Mayo Clinic considers liposuctions – a procedure where fat is removed from a specific part of the body and shapes the area – to be dangerous.
The risks include internal puncture, infection, kidney and heart problems.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
5 hours ago
- Daily Mail
Indignant Melania Trump boldly addresses breast implant rumors in resurfaced interview
Melania Trump didn't hold back when asked about long-standing rumors she'd had breast implants, quickly shutting down the speculation in a now-resurfaced interview. Speaking to GQ in 2016, the former model discussed her family, her relationship with President Donald Trump, and what her life looks like behind the scenes. During the chat, the First Lady, 55, also firmly denied going under the knife, insisting at the time that her figure was entirely natural. 'I didn't make any changes,' she told GQ with a scoff when asked directly if she had a boob job. At the time, she said she was against 'damaging' injections like Botox and credited her youthful appearance with simply taking good care of herself. 'A lot of people say I am using all the procedures for my face. I didn't do anything,' she continued. 'I live a healthy life, I take care of my skin and my body. I'm against Botox, I'm against injections; I think it's damaging your face, damaging your nerves. 'It's all me. I will age gracefully, as my mom does.' Despite Melania's denial of any work, plastic surgeon to the stars Dr. Gary Motykie theorized last year that she had spent $50,000 on 'maintenance work.' The surgeon told The Daily Mail: 'I don't see too much reason to be suspicious for a face lift... and I don't think she's had a brow lift either. '[But] I have noticed a change in her nose. Noses don't typically get smaller as they get older; they get bigger - but hers is definitely smaller and more defined, so I am very suspicious for at least one rhinoplasty [nose job]. 'I do think she's likely doing the maintenance work as well - fillers, particularly in the mid-face, cheeks, maybe a touch in the lips, and the standard Botox upkeep.' Another plastic surgeon, Dr Gary Linkov, argued the First Lady has had extensive cosmetic work, including a nose job, fillers, Botox, cheek implants, and even a facelift. Aside from speculated surgeries, Melania also keeps up her eye-catching physique with a healthy diet and strict exercise regimen. Both Pilates and tennis are a core part of Melania's fitness routine, as the activities are easy to do at home or at Mar-a-Lago. However, the Slovenian stunner previously revealed that she actually owes much of her slender physique to a small tweak she's made to her daily routine. In the same 2016 interview with GQ, the former supermodel said she wears ankle weights most days, which are said to increase calorie burn anywhere from five to 15 percent. But it's really Melania's diet that is the biggest contributor to her trim figure. The Vogue cover girl eats seven pieces of fresh fruit each day, with peaches and apples being her two favorites, according to Inside Edition. Melania also starts her day with a healthy fruit and vegetable smoothie made of ingredients like spinach, carrots, blueberries, apples, and fat-free yogurt.
Telegraph
2 days ago
- Telegraph
Why Brazil has built the world's largest mosquito factory
From the outside, the cavernous white building looks like any other factory. But step through the front door and the high pitched whine of insects signals that this is no ordinary assembly line: the new facility is producing mosquitoes. Billions of them. It sounds odd. Why would anyone breed more mosquitoes. Aren't there enough already buzzing around the globe, leaving in their wake a path of itchy bites and debilitating, sometimes fatal, fevers? Yet on Saturday, an team of scientists unveiled the world's largest mosquito factory in Curitiba, a city in southern Brazil. 'Nowhere in the world can produce the number of mosquitoes that will be produced here with this technology,' Alexandre Padilha, the country's health minister, said at the inauguration. '[The factory] represents an exercise in national sovereignty and innovation.' At its peak, the 5,000 square metre 'bio-factory' is set to churn out roughly 100 million mosquito eggs every week – more than five billion a year. These eggs, which carry a disease-blocking bacteria, will then be hatched in cities across the country, in the latest stage of an ambitious initiative to curb the spread of dengue. Colloquially known as 'breakbone fever', the mosquito-borne virus has wrought havoc across Latin America, with more than 13 million cases reported in the region last year – by far the worst epidemic on record. In Brazil alone, some 6.5 million people were infected, pushing the healthcare system to the brink, while 5,700 people died. 'You could see dengue everywhere – you'd go to the supermarket and there would be very few employees, because people were sick,' said Dr Luciano Moreira, a vector biologist and chief executive of Wolbito Brazil, one of the organisations behind the factory. 'So many friends and relatives were really ill… it was really a huge thing that affected everyone, rich and poor.' Now, after a year of construction, the factory in southern Brazil will start providing crucial reinforcements for Brazil's battle against the debilitating disease. That's because the Aedes aegypti mosquito eggs bred here carry a bacteria called Wolbachia, which blocks the mosquito's ability to transmit dengue. The Wolbachia bacteria is naturally found in a range of insects, though not the Aedes aegypti mosquito. When the insect is infected with the bacteria, it inhibits the dengue virus's ability to replicate inside it. In effect, the bacteria and the virus are competing for resources – and Wolbachia bacteria comes out on top. This has major ramifications for disease control, because it means the mosquito's bite no longer transmits the virus to people. The bacteria, which doesn't spread into humans, can also block Zika, yellow fever and chikungunya. 'We have seen that insecticides alone are not enough [to control dengue],' said Dr Moreira. 'You pay a lot, you have to damage the environment, and then the mosquitoes become resistant. So we really need to bring something else to the fight, and Wolbachia is one of these interventions. 'The advantage of Wolbachia is it's sustainable,' he added. 'It's biologically sound, it's not a chemical, and it doesn't interfere with the health of people or the environment or animals. So it holds a lot of promise.' It's not just Brazil that's in need of additional tools to fight dengue. In 1970, the virus had been detected in just seven countries; now roughly half the world's population are at risk of infection, with cases jumping to as many as 400 million a year. The increase – which is also occurring in Europe – has been driven by rising temperatures, rapid urbanisation and international travel. Experts hope that, alongside new vaccinations, Wolbachia could help turn the tide. There are two main ways the bacteria is deployed for disease control: either to suppress or replace mosquitoes. In Singapore, for instance, only male Wolbachia-infected mosquitoes are released. When they mate with wild, Wolbachia-free females, their eggs become infertile and do not hatch, causing the overall insect population to gradually get smaller over time. However, to be effective a constant stream of Wolbachia-carrying males have to be released. Brazil uses a different technique, reliant on both male and female Wolbachia-infected mosquitoes. When these bacteria-carrying insects mate, they pass the Wolbachia onto their offspring. The aim is that, after several generations, the majority of insects in any given area carry the bacteria, which then helps to suppress the spread of disease. 'In our case we want to have the replacement of the [mosquito] population, so that this becomes sustainable over time,' said Dr Moreira. 'We did a set of releases in 2014 and 2015. In those areas, Wolbachia is still in the mosquitoes. We don't need to do new releases again and again.' Since scientists at Monash University in Australia first identified the dengue-blocking capacity of Wolbachia some 15 years ago, multiple real-world studies have confirmed that this concept works – and it's safe. In 2020, a major randomised control trial in Indonesia found dengue cases dropped by 77 per cent in areas of Yogyakarta city where Wolbachia mosquitoes were released, while results in 2023 showed incidence fell by at least 94 per cent in three Colombian cities. But Dr Moreira warned the intervention is not an overnight fix. 'Wolbachia is a very powerful tool, especially when it is integrated with other measures,' he said. 'But it takes time for Wolbachia mosquitoes to establish. 'Politicians call in the middle of an epidemic and say they want us to come next month. We are clear and transparent that this won't help next month, it might take a year or two.' There are other limitations too, said Professor Eng Eong Ooi, a researcher at Duke-NUS Medical School's Emerging Infectious Diseases programme in Singapore. 'I think Wolbachia has shown great success but not universally. The environment, particularly how warm the place is, affects how well Wolbachia works,' he said. Mosquitoes were first released in the Brazilian capital Rio de Janeiro in a pilot in 2014. Studies have since shown drops in dengue of 38 per cent to 90 per cent in different areas of the city. The innovation has now become a central plank of the country's dengue control strategy, with Wolbachia mosquitoes so far released in 11 sites across Brazil. Until now, scientists were breeding roughly 15 million Wolbachia-carrying mosquito eggs every week, at a facility within the Fiocruz health institute in Rio. The biofactory in Curitiba will turbocharge the availability of disease-blocking insects, with scientists aiming to breed some 100 million mosquito eggs a week. 'The way we reared mosquitoes in the facilities for instance at Fiocrux, was a simple way: in trays and with lots of labour and hand processes,' said Dr Moreira. 'With the creation of our big factory now, we are bringing new equipment. We have machines to hatch the eggs… and we feed mosquitoes with automated devices.' He added that the facility also has a highly-controlled environment, to optimise conditions for the eggs, larvae and mosquitoes. Temperatures range from 27C to 29C depending on the stage of the life cycle, with humidity at 70 to 80 per cent, while insects are fed sugar, fish food and horse blood (a replacement for biting live animals, including humans). But only a small proportion of the eggs actually hatch in the factory. The vast majority will be shipped by car, plane and boat across the vast country as eggs, before local health officials add water and rear the larvae. 'We dry the eggs, and they don't hatch until they [come] into contact with the water,' said Dr Moreira. 'We put the eggs in capsules, or we can ship in filter paper. They can be [stored] for two or three months, they will still survive.' He added that the government has earmarked 40 cities, each home to more than 100,000 people, where they would like these eggs to be sent. Six cities have already been selected, where the first Curitiba-bred mosquitoes will be released as early as August. 'It will be exciting to get to that moment,' said Dr Moreira, who was working in the lab in Australia in 2009, when scientists first identified Wolbachia's disease-blocking potential. 'It's been a long time coming, slowly going through the scientific evidence and expanding into a robust programme in Brazil,' he added. 'Wolbachia is only one element of the solution for dengue, but I think it will be a very significant one for the country.'
Reuters
2 days ago
- Reuters
India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says
HYDERABAD July 23 (Reuters) - Dr Reddy's Laboratories ( opens new tab plans to launch a cheaper copycat version of Novo Nordisk's ( opens new tab blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday. Drugmakers are racing to get a share of the global obesity drug market, expected to generate around $150 billion in sales by the early 2030s, after Denmark-based Novo and its U.S. rival Eli Lilly (LLY.N), opens new tab saw extraordinary demand for their medicines. Dr Reddy's initially plans to launch the generic version of semaglutide - the active ingredient of Novo's Wegovy and diabetes medicine Ozempic - in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said. "U.S. and Europe will open later... (and) all the other Western markets will be open between 2029 to 2033," Israeli said a press conference to discuss the company's earnings. He expects the generic drug to generate 'hundreds of millions of dollars' in sales for the company. Semaglutide's patent is expected to expire in several countries next year, including in India in March. Novo Nordisk had sued Dr Reddy's in May alleging patent infringement of semaglutide, according to documents seen by Reuters. Dr Reddy's has filed relevant regulatory applications in all the countries it is planning to launch the generic version in, Israeli said. Other Indian drugmakers, including Cipla ( opens new tab, Lupin ( opens new tab, Biocon ( opens new tab, Sun Pharma ( opens new tab, also plan to launch these generic weight-loss drugs after Novo's and Lilly's success. Novo launched Wegovy in India last month, following Lilly's Mounjaro launch for weight-loss and diabetes management. The drugs belong to a class called GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer. Dr Reddy's also aims to launch 26 GLP-1 drugs within the next decade, Israeli said.
